Pyxis Oncology (PYXS) EBIAT (2024 - 2025)
Pyxis Oncology (PYXS) has disclosed EBIAT for 2 consecutive years, with -$18.1 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 49.06% to -$18.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$79.6 million through Dec 2025, down 3.01% year-over-year, with the annual reading at -$79.6 million for FY2025, 2.93% down from the prior year.
- EBIAT for Q4 2025 was -$18.1 million at Pyxis Oncology, up from -$22.0 million in the prior quarter.
- The five-year high for EBIAT was -$3.3 million in Q1 2024, with the low at -$35.5 million in Q4 2024.